Evidence map›Paper›PMID 35782147›Full record

ArticleFrontiers in cellular and infection microbiology2022

Expanding the Malaria Antibody Toolkit: Development and Characterisation of

Adéla Nacer, Gaily Kivi, Raini Pert, Erkki Juronen, Pavlo Holenya, Eduardo Aliprandini, Rogerio Amino, Olivier Silvie, Doris Quinkert, Yann Le Duff and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Host-parasite interactions duringFrontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Adéla NacerDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
Gaily KiviIcosagen Cell Factory OÜ, Tartumaa, Estonia.
Raini PertIcosagen Cell Factory OÜ, Tartumaa, Estonia.
Erkki JuronenIcosagen Cell Factory OÜ, Tartumaa, Estonia.
Pavlo HolenyaResearch and Development, JPT Peptide Technologies GmbH, Berlin, Germany.
Eduardo AliprandiniMalaria Infection & Immunity Unit, Institut Pasteur, Paris, France.
Rogerio AminoMalaria Infection & Immunity Unit, Institut Pasteur, Paris, France.
Olivier SilvieSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France.
Doris QuinkertDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.
Yann Le DuffCentre for Aids Reagents, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
Matthew HurleyCentre for Aids Reagents, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
Ulf ReimerResearch and Development, JPT Peptide Technologies GmbH, Berlin, Germany.
Andres ToverIcosagen Cell Factory OÜ, Tartumaa, Estonia.
Simon J DraperDepartment of Biochemistry, University of Oxford, Oxford, United Kingdom.
Sarah GilbertCentre for Aids Reagents, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
Mei Mei HoDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
Paul W BowyerDivision of Bacteriology, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency (MHRA), Potters Bar, United Kingdom.
National Institute for Biological Standards and Control · GBIcosagen (Estonia) · EEInstitut Pasteur · FRJPT Peptide Technologies (Germany) · DEUniversity of Oxford · GBSorbonne Université · FR

Funding

Molecular-Genetic Mechs Underlying Effects of Anti-inflammatory/Analgesic DrugsZ01NR000014 · NINR · NATIONAL INSTITUTE OF NURSING RESEARCH · PI DIONNE, RAYMOND A · 2006 to 2008
$1.8M
Intramural NIH HHS Z01 NR000014Wellcome Trust 106917/Z/15/Z
6 · The paper itself

Abstract

Malaria, an infection caused by apicomplexan parasites of the genus

Indexed as

Antibodies, MonoclonalPlasmodium falciparumAnimalsAntibodies, ProtozoanCarrier ProteinsErythrocytesHumansAntibodies, MonoclonalAntibodies, ProtozoanCarrier ProteinsRH5 protein, Plasmodium falciparumassay developmentmalariamonoclonal antibodiesPfCSPPfCyRPAPfRH5Plasmodium falciparumstandardisation

Identifiers

PMID35782147
PMCPMC9243361
OpenAlexW4282984308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.